A registered dietitian will teach you how to improve your health by making better food choices at EvergreenHealth Nutrition Counseling in Kirkland, WA.

Get advanced treatment for issues with the colon, rectum and anus at EvergreenHealth in Kirkland, WA, including minimally invasive and robotic surgery.

Learn about the comprehensive imaging services at EvergreenHealth locations throughout east King and Snohomish counties.

Check out the clinical research trials underway at EvergreenHealth in Kirkland, WA.

With EvergreenHealth Signature Care, you’ll have high-quality primary care that caters to your family’s needs, preferences, and convenience.

Workshops and support groups help you grieve the death of a loved one at EvergreenHealth Grief and Bereavement Support in Kirkland, WA.

Get in-home counseling and case management for qualifying residents in King County from the Behavioral Health program at EvergreenHealth in Kirkland, WA.

Get the tools to kick your addiction to drugs and alcohol, improve your personal health and relationships, and better function within your family and work.

Learn about home health care services available in King and Snohomish counties from EvergreenHealh Home Care in Kirkland, WA.

Learn how we deliver the birth experience of your dreams at EvergreenHealth's Family Maternity Center in Kirkland, WA with OBGYNs and certified nurse midwives.

Alpha-glucosidase inhibitors are a less popular class of medicines for Type 2 diabetes...

The medicines highlighted this week are from the newest class of diabetes drugs to hit the scene: SGLT2 inhibitors.

This week's choice of topic is the class of diabetes drugs known as meglitinides.

This week, we'll look at a much newer class of medicines called DPP-4 inhibitors. DPP-4 stands for "dipeptidyl peptidase-4," a type of enzyme.

The two thiazolidinediones (TZDs) available are pioglitazone (brand name Actos) and rosiglitazone (Avandia), and they both were approved in 1999.

The leading source for trustworthy and timely health and medical news and information. Providing credible health information, supportive community, and educational services by blending award-winning expertise in content, community services, expert commentary, and medical review.

This week, we'll wrap up the diabetes pills series with a focus on two lesser-known (and lesser-used) diabetes medicines.

That classic summertime fruit, watermelon, has a lot more to offer than sweet taste. It's chock-full of nutrients that help your body thrive. Check out what you get when you include watermelon as part of a healthy diet.

As a gut-restricted non-absorbed therapy, polymeric bile acid sequestrants (BAS) play an important role in managing hyperlipidemia and hyperglycemia. Similarly, non-absorbable sequestrants of dietary phosphate have been used for the management of hyperphosphatemia in end stage renal disease. To evaluate the potential utility of such polymer sequestrants to treat type 2 diabetes (T2D) and its associated renal and cardiovascular complications, we synthesized a novel polymeric sequestrant, SAR442357 possessing optimized bile acid (BA) and phosphate sequestration characteristics. Long-term treatment of T2D obese ZSF1 rats with SAR442357 resulted in enhanced sequestration of BAs and phosphate in the gut, improved glycemic control, lowering plasma cholesterol and triglycerides and attenuated diabetic kidney disease (DKD) progression. In comparison, colesevelam, a BAS with poor phosphate binding property did not prevent DKD progression, while losartan, an angiotensin II receptor blocker that is widely used to treat DKD, showed no effect on hyperglycemia. Analysis of hepatic gene expression levels of the animals treated with SAR442357 revealed upregulation of genes responsible for the biosynthesis of cholesterol and BAs, providing clear evidence of target engagement and mode of action of the new sequestrant. Additional hepatic gene expression pathway changes were indicative that there was interruption of the enterohepatic BA cycle. Histopathological analysis of ZSF1 rat kidneys treated with SAR442357 further supported its nephroprotective properties. Collectively, these findings reveal the pharmacological benefit of simultaneous sequestration of BAs and phosphate in treating T2D and its associated comorbidities and cardiovascular complications. Significance Statement A new non-absorbed polymeric sequestrant with optimum phosphate and bile salt sequestration properties was developed as a treatment option for DKD. The new polymeric sequestrant offered combined pharmacological benefits including glucose regulation, lipid lowering and attenuation of DKD progression in a single therapeutic agent.

This week, we'll wrap up the diabetes pills series with a focus on two lesser-known (and lesser-used) diabetes medicines.

As a gut-restricted, nonabsorbed therapy, polymeric bile acid sequestrants (BAS) play an important role in managing hyperlipidemia and hyperglycemia. Similarly, nonabsorbable sequestrants of dietary phosphate have been used for the management of hyperphosphatemia in end-stage renal disease. To evaluate the potential utility of such polymer sequestrants to treat type 2 diabetes (T2D) and its associated renal and cardiovascular complications, we synthesized a novel polymeric sequestrant, SAR442357, possessing optimized bile acid (BA) and phosphate sequestration characteristics. Long-term treatment of T2D obese cZucker fatty/Spontaneously hypertensive heart failure F1 hybrid (ZSF1) with SAR442357 resulted in enhanced sequestration of BAs and phosphate in the gut, improved glycemic control, lowering of serum cholesterol, and attenuation of diabetic kidney disease (DKD) progression. In comparison, colesevelam, a BAS with poor phosphate binding properties, did not prevent DKD progression, whereas losartan, an angiotensin II receptor blocker that is widely used to treat DKD, showed no effect on hyperglycemia. Analysis of hepatic gene expression levels of the animals treated with SAR442357 revealed upregulation of genes responsible for the biosynthesis of cholesterol and BAs, providing clear evidence of target engagement and mode of action of the new sequestrant. Additional hepatic gene expression pathway changes were indicative of an interruption of the enterohepatic BA cycle. Histopathological analysis of ZSF1 rat kidneys treated with SAR442357 further supported its nephroprotective properties. Collectively, these findings reveal the pharmacological benefit of simultaneous sequestration of BAs and phosphate in treating T2D and its associated comorbidities and cardiovascular complications. SIGNIFICANCE STATEMENT A new nonabsorbed polymeric sequestrant with optimum phosphate and bile salt sequestration properties was developed as a treatment option for DKD. The new polymeric sequestrant offered combined pharmacological benefits including glucose regulation, lipid lowering, and attenuation of DKD progression in a single therapeutic agent.